MorphoSys (MOR) Given a €65.00 Price Target by Royal Bank of Canada Analysts
Royal Bank of Canada set a €65.00 ($75.58) price objective on MorphoSys (ETR:MOR) in a report issued on Friday, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.
Several other analysts also recently weighed in on MOR. Berenberg Bank set a €108.00 ($125.58) price target on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, May 15th. Deutsche Bank set a €125.00 ($145.35) price objective on shares of MorphoSys and gave the company a buy rating in a research report on Thursday, May 9th. Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the company a neutral rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of MorphoSys and gave the company a buy rating in a research report on Friday. Finally, Independent Research set a €96.00 ($111.63) price objective on shares of MorphoSys and gave the company a neutral rating in a research report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. MorphoSys presently has an average rating of Hold and a consensus target price of €100.78 ($117.18).
MorphoSys stock opened at €93.25 ($108.43) on Friday. The company has a quick ratio of 7.53, a current ratio of 7.75 and a debt-to-equity ratio of 8.65. The firm has a market capitalization of $2.94 billion and a price-to-earnings ratio of -50.19. MorphoSys has a twelve month low of €76.45 ($88.90) and a twelve month high of €124.90 ($145.23).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.